TW200938223A - Monoclonal antibody partner molecule conjugates directed to protein tyrosine kinase 7 (PTK7) - Google Patents

Monoclonal antibody partner molecule conjugates directed to protein tyrosine kinase 7 (PTK7) Download PDF

Info

Publication number
TW200938223A
TW200938223A TW097145713A TW97145713A TW200938223A TW 200938223 A TW200938223 A TW 200938223A TW 097145713 A TW097145713 A TW 097145713A TW 97145713 A TW97145713 A TW 97145713A TW 200938223 A TW200938223 A TW 200938223A
Authority
TW
Taiwan
Prior art keywords
antibody
seq
group
human
cancer
Prior art date
Application number
TW097145713A
Other languages
English (en)
Chinese (zh)
Inventor
Jonathan Alexander Terrett
Chetana Rao-Naik
Chin Pan
Original Assignee
Medarex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medarex Inc filed Critical Medarex Inc
Publication of TW200938223A publication Critical patent/TW200938223A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW097145713A 2007-11-30 2008-11-26 Monoclonal antibody partner molecule conjugates directed to protein tyrosine kinase 7 (PTK7) TW200938223A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US503407P 2007-11-30 2007-11-30

Publications (1)

Publication Number Publication Date
TW200938223A true TW200938223A (en) 2009-09-16

Family

ID=40718460

Family Applications (1)

Application Number Title Priority Date Filing Date
TW097145713A TW200938223A (en) 2007-11-30 2008-11-26 Monoclonal antibody partner molecule conjugates directed to protein tyrosine kinase 7 (PTK7)

Country Status (11)

Country Link
US (1) US20120027782A1 (cg-RX-API-DMAC7.html)
EP (1) EP2229187A2 (cg-RX-API-DMAC7.html)
JP (1) JP2011505146A (cg-RX-API-DMAC7.html)
KR (1) KR20100101124A (cg-RX-API-DMAC7.html)
CN (1) CN101939028A (cg-RX-API-DMAC7.html)
AR (1) AR069903A1 (cg-RX-API-DMAC7.html)
AU (1) AU2008334076A1 (cg-RX-API-DMAC7.html)
CL (1) CL2008003527A1 (cg-RX-API-DMAC7.html)
MX (1) MX2010005966A (cg-RX-API-DMAC7.html)
TW (1) TW200938223A (cg-RX-API-DMAC7.html)
WO (1) WO2009073546A2 (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007067730A2 (en) 2005-12-08 2007-06-14 Medarex, Inc. Human monoclonal antibodies to protein tyrosine kinase 7 ( ptk7 ) and their use
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
RU2562232C2 (ru) 2008-11-03 2015-09-10 Синтарга Б.В. Новые аналоги сс-1065 и их конъюгаты
PT3056203T (pt) 2010-04-21 2018-02-15 Syntarga Bv Conjugados de análogos de cc-1065 e ligantes bifuncionais
EP2380909A1 (en) * 2010-04-26 2011-10-26 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. PTK-7 protein involved in breast cancer
SA112330278B1 (ar) * 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
US8852599B2 (en) * 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
CA2843504C (en) * 2011-08-12 2020-08-25 Ascendis Pharma A/S Protein carrier-linked prodrugs
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
TWI727919B (zh) * 2013-12-19 2021-05-21 美商西雅圖遺傳學公司 與標的-藥物結合物併用之亞甲基胺基甲酸酯連接物
JP6419844B2 (ja) 2014-01-10 2018-11-07 シントン・バイオファーマシューティカルズ・ビー．ブイ．Ｓｙｎｔｈｏｎ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｂ．Ｖ． Ｃｙｓ連結された抗体−薬物コンジュゲートの精製方法
EP3137114B8 (en) 2014-04-30 2021-08-04 Pfizer Inc. Anti-ptk7 antibody-drug conjugates
MY181896A (en) 2014-06-06 2021-01-12 Bristol Myers Squibb Co Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
US10100129B2 (en) 2014-11-21 2018-10-16 Bristol-Myers Squibb Company Antibodies against CD73 and uses thereof
EA038349B1 (ru) 2014-11-21 2021-08-12 Бристол-Маерс Сквибб Компани Антитела, содержащие модифицированные константные участки тяжелой цепи
EP3237448A1 (en) 2014-12-23 2017-11-01 Bristol-Myers Squibb Company Antibodies to tigit
JP6983776B2 (ja) 2015-11-19 2021-12-17 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company グルココルチコイド誘発腫瘍壊死因子受容体（ｇｉｔｒ）に対する抗体およびその使用
KR20220033522A (ko) 2016-03-04 2022-03-16 브리스톨-마이어스 스큅 컴퍼니 항-cd73 항체와의 조합 요법
KR102573778B1 (ko) 2017-02-17 2023-08-31 브리스톨-마이어스 스큅 컴퍼니 알파-시뉴클레인에 대한 항체 및 그의 용도
KR20200006115A (ko) 2017-05-16 2020-01-17 브리스톨-마이어스 스큅 컴퍼니 항-gitr 효능제 항체에 의한 암의 치료
US20200299400A1 (en) 2017-05-25 2020-09-24 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
EP3876998A1 (en) 2018-11-05 2021-09-15 Synaffix B.V. Antibody-conjugates for targeting of tumours expressing trop-2
CN110845480B (zh) * 2019-11-22 2022-03-15 荣昌生物制药(烟台)股份有限公司 一种双功能细胞毒素及其用途
WO2022015113A1 (ko) * 2020-07-16 2022-01-20 연세대학교 산학협력단 Ptk7에 특이적으로 결합하는 항체 및 이의 용도
CN115894696A (zh) * 2021-08-18 2023-04-04 和迈生物科技有限公司 抗ptk7单域抗体及其应用
IL315366A (en) * 2022-03-23 2024-11-01 Synaffix Bv Antibody pairs for targeting PTK7-expressing tumors
GB202212077D0 (en) 2022-08-18 2022-10-05 Tribune Therapeutics Ab Agents that inhibit ccn ligand-induced signalling for treating disease
WO2024054030A1 (ko) * 2022-09-06 2024-03-14 연세대학교 산학협력단 항-ptk7 항체 및 이의 용도
CN118852442A (zh) * 2023-04-26 2024-10-29 上海麦科思生物医药有限公司 抗ptk7抗体及其用途
WO2025040588A1 (en) * 2023-08-18 2025-02-27 Oncoinvent As Monoclonal anti-ptk7 antibodies and derivatives
AR133955A1 (es) * 2023-09-26 2025-11-19 Profoundbio Us Co Agentes de unión a ptk7, conjugados de éstos y métodos de uso de los mismos

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2459308A1 (en) * 2001-09-07 2003-03-20 Dale L. Boger Cbi analogues of cc-1065 and the duocarmycins
GB0219776D0 (en) * 2002-08-24 2002-10-02 Oxford Glycosciences Uk Ltd A protein involved in carcinoma
CA2564076C (en) * 2004-05-19 2014-02-18 Medarex, Inc. Chemical linkers and conjugates thereof
RU2402548C2 (ru) * 2004-05-19 2010-10-27 Медарекс, Инк. Химические линкеры и их конъюгаты
CN101312748A (zh) * 2005-09-26 2008-11-26 梅达莱克斯公司 抗体-药物轭合物和使用方法
WO2007067730A2 (en) * 2005-12-08 2007-06-14 Medarex, Inc. Human monoclonal antibodies to protein tyrosine kinase 7 ( ptk7 ) and their use

Also Published As

Publication number Publication date
WO2009073546A3 (en) 2009-12-30
CL2008003527A1 (es) 2009-10-09
KR20100101124A (ko) 2010-09-16
MX2010005966A (es) 2010-06-15
CN101939028A (zh) 2011-01-05
US20120027782A1 (en) 2012-02-02
EP2229187A2 (en) 2010-09-22
AU2008334076A1 (en) 2009-06-11
AR069903A1 (es) 2010-03-03
WO2009073546A2 (en) 2009-06-11
JP2011505146A (ja) 2011-02-24

Similar Documents

Publication Publication Date Title
TW200938223A (en) Monoclonal antibody partner molecule conjugates directed to protein tyrosine kinase 7 (PTK7)
JP5401639B2 (ja) タンパク質チロシンキナーゼ７（ｐｔｋ７）に対するヒトモノクローナル抗体およびそれらの使用
CN101636502B (zh) 结合cd19的人类抗体及其用途
JP5535074B2 (ja) メソテリンに結合するヒト抗体およびその使用
KR101552735B1 (ko) 씨디22에 결합하는 인간 항체 및 이의 용도
US8420084B2 (en) Fully human antibodies specific to CADM1
US20110085970A1 (en) Anti-b7h4 monoclonal antibody-drug conjugate and methods of use
CN101605906A (zh) 结合cd70的人类抗体及其用途
US20090162372A1 (en) Fibronectin ed-b antibodies, conjugates thereof, and methods of use
JP2011505371A (ja) 抗−ｒｇ−１抗体の複合体
HK1164332B (en) Fully human antibodies specific to cadm1
HK1164332A (en) Fully human antibodies specific to cadm1
MX2008006792A (en) Human monoclonal antibodies to protein tyrosine kinase 7 ( ptk7 ) and their use
HK1185085B (en) Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fuco-syl-gm1